851048-51-6

Basic information

• Product Name: 4-(TETRAHYDROPYRAN-4-YLOXY)BENZOIC ACID
• Synonyms: 4-(TETRAHYDROPYRAN-4-YLOXY)BENZOIC ACID;4-[(Tetrahydro-2H-pyran-4-yl)oxy]benzoic acid
• CAS NO: 851048-51-6
• Molecular Formula: C₁₂H₁₄O₄
• Molecular Weight: 222.23716
• Mol File: 851048-51-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 185 °C
• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(TETRAHYDROPYRAN-4-YLOXY)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TETRAHYDROPYRAN-4-YLOXY)BENZOIC ACID(851048-51-6)
• EPA Substance Registry System: 4-(TETRAHYDROPYRAN-4-YLOXY)BENZOIC ACID(851048-51-6)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 851048-51-6(Hazardous Substances Data)

Usage

General Description

4-(Tetrahydropyran-4-yloxy)benzoic acid is a chemical compound that consists of a benzene ring with a carboxylic acid group and a tetrahydropyran-4-yloxy group attached to it. 4-(TETRAHYDROPYRAN-4-YLOXY)BENZOIC ACID is a derivative of benzoic acid and is commonly used in organic synthesis and medicinal chemistry. It has potential applications as a building block in the synthesis of various pharmaceuticals and agrochemicals. The tetrahydropyran-4-yloxy group confers unique properties to this compound, making it useful in the development of new drugs and materials. Additionally, the benzoic acid moiety provides potential for interactions with biological targets, making it a valuable chemical for drug discovery and development.

Upstream product

• 2081-44-9 Tetrahydro-pyran-4-ol 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 1125474-25-0 methyl 4-((tetrahydro-2H-pyran-4-yl)oxy)benzoate 
• 851048-50-5 ethyl 4-(tetrahydro-2H-pyran-4-yloxy)benzoate 

Downstream Products

• 892501-93-8 4-(tetrahydro-2H-pyran-4-yloxy)benzoyl chloride 
• 1125474-24-9 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine hydrochloride 
• 1125474-22-7 (4-isopropylpiperazin-1-yl)(4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)methanone 
• 1442121-04-1 N-(2-methoxyethyl)-4-methyl-2-({1-[4-(3,4,5,6-tetrahydro-2H-pyran-4-yloxy)benzoyl]piperidin-4-yl}methyl)-2H-indazole-5-carboxamide 

Relevant articles and documents

Identification of highly potent N-acylethanolamine acid amidase (NAAA) inhibitors: Optimization of the terminal phenyl moiety of oxazolidone derivatives

N-acylethanolamine acid amidase (NAAA) is a cysteine hydrolase that participates in the deactivation of fatty acid ethanolamides, such as palmitoylethanolamide (PEA). NAAA inhibition may provide a potential therapeutic strategy for the treatment of diseases in which higher PEA level is desired. In the present study, we reported the structure-activity relationship (SAR) studies for oxazolidone derivatives as NAAA inhibitors. A series of substituents or alkyl replacements for the terminal phenyl ring of oxazolidone derivatives were examined. The results showed that the inhibition potency of these oxazolidone derivatives towards NAAA depends on the sizes, flexibility, and lipophilicity of the terminal groups. SAR results suggested that small lipophilic 3-phenyl substituents or hydroxy-containing 4-phenyl substituents were preferable for optimal potency. Furthermore, the distal aliphatic replacement is also preferred for high inhibitory potency. Rapid dilution and kinetic analysis suggested that oxazolidone derivatives with different terminal phenyl moieties inhibited NAAA via different mechanisms. This study identified several highly potent NAAA inhibitors, including 1a (F215, IC50 = 0.009 μM), 1o (IC50 = 0.061 μM) and 2e (IC50 = 0.092 μM), and also determined structural requirements of oxazolidone derivatives for potent inhibition against NAAA.

PIPERAZINE DERIVATIVE HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR

The present invention relates to 1-(1-methylethyl)-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}piperazine (Formula) or a pharmaceutically acceptable salt thereof, in particular the hydrochloride salt thereof and crystalline forms of the hydrochloride salt; to processes for the preparation of the compound or its salt; to compositions containing it; and to its use in the treatment or prophylaxis of neurological or psychiatric diseases, such as cognitive impairment, fatigue or a sleep disorder, for example in a mammal such as a human. The compound or a salt thereof has affinity for and is an antagonist and/or inverse agonist of the histamine H3 receptor.